10x Genomics

American biotechnology company 10x Genomics logo.svg 10x Genomics, Inc. 10X Technologies, Inc. Public TXG (Class A) Russell 1000 component 2012 Serge Saxonov Ben Hindson Kevin Ness Pleasanton, California, U.S. Serge Saxonov (CEO) Ben Hindson (president and CSO) 611 million yes (2024) -195 million (2024) -183 million (2024) 919 million (2024) 710 million (2024) 1,306 (2024) 10xgenomics.com SEC Form 10-K https://www.sec.gov/ix?doc=/Archives/edgar/data/1770787/000177078725000013/txg-20241231.htm United States Securities and Exchange Commission February 13, 2025 February 13, 2025https://www.forbes.com/sites/matthewherper/2018/12/10/buzzy-startup-10x-genomics-buys-spatial-transcriptomics-in-bet-on-genetic-tools/ Buzzy Startup 10x Genomics Buys Spatial Transcriptomics In Bet On Genetic Tools Herper Matthew Forbes 2019-01-28 10x Genomics, Inc. is an American biotechnology company that designs and manufactures sequencing technologies for use in scientific research, with a focus on product development for single-cell and spatial omics. History 10x Genomics was founded in 2012 by Serge Saxonov, Ben Hindson and Kevin Ness to create advanced testing equipment for use in cellular biology.https://www.genomeweb.com/business-news/10x-genomics-founders-prevail-arbitration-dispute-bio-rad 10X Genomics Founders Prevail in Arbitration Dispute With Bio-Rad GenomeWeb 21 December 2015 2019-01-28 Prior to starting the company, Saxonov was the founding architect, and director of research and development at 23andMe. Ness left 10x Genomics in December 2016http://www.innovationews.com/Muse-bio-appoints-Kevin-Ness-new-CEO/ Muse bio appoints Kevin Ness new CEO 2016-12-09 InnovatioNews 2019-01-28 and in 2018, Justin McAnear, Tesla's former finance chief joined the company as CFO.https://www.axios.com/teslas-former-finance-chief-becomes-cfo-of-biotech-startup-1538754701-de3b7ce4-1af2-4500-b07d-180d5d252055.html Tesla's former finance chief becomes CFO of genomics startup Axios 2019-01-28 In August 2018, the company announced its first acquisition, Epinomics, a biotechnology company focused on the development of new techniques for epigenetics research.https://www.cnbc.com/2018/08/28/sofbtank-backed-10x-genomics-buys-epinomics.html SoftBank-backed 10x Genomics buys pinomics Farr Christina 2018-08-28 www.cnbc.com 2019-01-28 Four months later, 10x Genomics acquired Spatial Transcriptomics, a biotechnology company working in the field of spatial genomics.https://www.genomeweb.com/sequencing/10x-genomics-acquires-spatial-transcriptomics 10x Genomics Acquires Spatial Transcriptomics GenomeWeb 10 December 2018 2019-01-28 In November 2018, 10x Genomics announced expansion plans including opening a manufacturing facility in Pleasanton, California in early 2019.https://www.bizjournals.com/sanfrancisco/news/2018/11/29/10x-genomics-pleasanton-headquarters-lease-biotech.html Fast-growing biotech leases up 150,000 square feet in Pleasanton for new headquarters Torres Blanca San Francisco Business Times 2019-01-28 10x Genomics announced its initial public offering on September 12, 2019, raising $390M.https://www.cnbc.com/2019/09/12/10x-genomics-txg-biotech-start-up-surges-in-ipo-debut.html Biotech start-up 10x Genomics surges in IPO debut Setty Ganesh 2019-09-12 CNBC en 2019-10-07https://www.fiercebiotech.com/medtech/10x-genomics-ipo-rockets-past-a-390m-raise 10x Genomics' IPO rockets past a $390M raise FierceBiotech en 2019-10-07 The company had revenues of $3.32 million in 2015, $27.48 million in 2016, $71.18 million in 2017,https://www.bizjournals.com/sanfrancisco/news/2018/10/30/fast-100-2018-10x-genomics-gene-imaging-tools.html 10x Genomics takes gene imaging and analysis tools to the big leagues Hepler Lauren San Francisco Business Times 2019-01-28 $145 million in 2018,https://www.genomeweb.com/business-news/jp-morgan-healthcare-day-one-10x-genomics-myriad-bruker-konica-minolta-geisinger JP Morgan Healthcare, Day One: 10x Genomics, Myriad, Bruker, Konica Minolta, Geisinger GenomeWeb 8 January 2019 2019-01-28 and $618.7 million in 2023.SEC Form 10-K https://www.sec.gov/ix?doc=/Archives/edgar/data/1770787/000177078724000017/txg-20231231.htm United States Securities and Exchange Commission February 15, 2024 4, 97 February 15, 2024 Arbitration and lawsuit Saxonov, Hindson, and Ness worked together at Quantalife prior to its acquisition by Bio-Rad in 2011 and left in 2012 to launch 10x Genomics. In 2014 an arbitration dispute was brought against the three cofounders by Bio-Rad, claiming they had breached obligations they allegedly owed to Bio-Rad after it acquired Quantalife. In 2015 an arbitrator determined that the founders of 10x Genomics had not breached their obligation to Bio-Rad when they left the company and denied its claims. In November 2018, a Delaware jury found that 10x Genomics infringed on several University of Chicago patents that were exclusively licensed to Bio-Rad. 10x Genomics were ordered to pay $24 million in damages to Bio-Rad and a 15% royalty on sales.https://www.law.com/therecorder/2018/11/15/bio-rad-snares-24-million-patent-infringement-verdict/ Bio-Rad Snares $24 Million Patent Infringement Verdict 15 November 2018 Scott Graham The Recorder 2019-01-28https://www.genomeweb.com/pcr/bio-rad-awarded-24m-10x-genomics-patent-infringement-lawsuit Bio-Rad Awarded $24M in 10x Genomics Patent Infringement Lawsuit GenomeWeb 14 November 2018 2019-01-28 10x Genomics appealed the verdict but the decision was upheld in August 2020.Graham Scott Bio-Rad Sounds Poised to Win on Money, Lose on Injunction https://www.law.com/nationallawjournal/2020/04/10/bio-rad-sounds-poised-to-win-on-money-lose-on-injunction/?slreturn=20200708064940 8 August 2020 National Law Journal 10 April 2020 enBio-Rad wins appeal in 10x Genomics patent infringement ruling https://www.scienceboard.net/index.aspx?sec=sup&sub=imm&pag=dis&ItemID=1131 8 August 2020 Scienceboard.net 5 August 2020 In July 2021, Bio-Rad and 10x Genomics settled all outstanding lawsuits brought in American federal as well as international courts for an undisclosed amount and the rights for the companies to license each other's patents for single-cell analysis.Brittain Blake Bio-Rad, 10x Genomics settle genomics patent war https://www.reuters.com/legal/transactional/bio-rad-10x-genomics-settle-genomics-patent-war-2021-07-27/ June 21, 2022 Reuters July 27, 2021 Partnerships In 2025, 10x Genomics announced it was partnering with Arc Institute to support Arc's virtual cell atlas and virtual cell competition.https://arcinstitute.org/news/virtual-cell-challenge-2025 Arc Institute launches its inaugural virtual cell competition using AI to solve one of biology’s biggest challenges References Category:Biotechnology companies of the United States Category:Genomics companies Category:2012 establishments in California Category:Companies based in Pleasanton, California Category:Biotechnology companies established in 2012 Category:American companies established in 2012 Category:2019 initial public offerings Category:Companies listed on the Nasdaq